Vericel Corp (VCEL) SEC Filings

Soleus Capital Master Fund, L.P. and related Soleus entities report beneficial ownership of Vericel Corp common stock on an amended Schedule 13G. They collectively report 1,458,882 shares of Vericel, representing 2.8% of the common stock outstanding, placing them in the category of ownership of 5 percent or less of the class.

All reported voting and dispositive authority over these shares is shared, with no sole power to vote or dispose. The ownership percentage is based on 51,206,614 shares outstanding as of July 24, 2026, as referenced from Vericel’s Form 10-Q. Each Soleus-related entity and Guy Levy disclaim beneficial ownership beyond what is required for Section 13(d) reporting.

Kevin McLaughlin filed a notice of proposed sale of 7,000 shares of common stock of VCEL through Fidelity Brokerage Services LLC on or after 08/12/2026, in connection with a stock option exercise. In the past three months, he sold 7,000 shares on 05/13/2026 for $229,777.45.

Vericel Corp Chief Operating Officer Michael Halpin exercised stock options to acquire 10,000 shares of common stock at an exercise price of $16.66 per share, then sold 10,000 shares at $46.84 per share on August 3, 2026.

The options exercised are part of a grant originally covering 76,250 shares that vested quarterly beginning May 6, 2019, with 26,250 options reported remaining outstanding. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on December 2, 2025, and Halpin’s direct holdings include shares acquired under Vericel’s 2015 Employee Stock Purchase Plan.

Vericel Corporation insider Michael Halpin filed to sell 10,000 shares of common stock of Vericel Corporation (through Fidelity Brokerage Services LLC). The planned sale, listed for 08/03/2026 on NASDAQ, reflects an aggregate market value of $459,800.00. The shares are to be sold for cash and are tied to a stock option exercise from the issuer dated 08/03/2026. The filing also notes that Halpin sold 10,000 shares of common stock on 06/18/2026 for proceeds of $402,401.05 during the prior three months.

Vericel Corp Principal Accounting Officer Jonathan Siegal exercised stock options covering 4,500 shares of common stock on July 30, 2026 at exercise prices of $34.90 and $29.82 per share, then sold 4,500 shares at $48.90 per share under an automatic Rule 10b5-1 trading plan adopted on December 10, 2025.

VCEL insider Jonathan Siegal filed a notice of proposed sale of 4,500 shares of common stock through Fidelity Brokerage Services LLC, with an indicated aggregate sale price of $220,050.00 on July 30, 2026. The shares relate to a stock option exercise for cash dated July 30, 2026. In the prior three months, Siegal reported sales of 3,433 shares for $130,454.00 on May 6, 2026, 1,422 shares for $57,591.00 on May 7, 2026, and 2,732 shares for $122,666.80 on June 26, 2026.

Vericel Corporation reported improved financial performance for the quarter ended June 30, 2026. Total revenue was 77,457 (amounts in thousands), up 22.5% year over year, driven mainly by MACI at 65,506, Epicel at 10,404 and NexoBrid at 1,547. Gross profit reached 56,402 and income from operations was 434, producing net income of 2,206, or $0.04 per diluted share, versus a net loss of 553 a year earlier.

For the first six months of 2026, revenue was 145,882 (amounts in thousands) and the net loss narrowed to 4,096 from 11,799. As of June 30, 2026, cash and cash equivalents were $125.4 million and investments were $102.1 million. Operating activities provided 32,574 (amounts in thousands) of cash, and there were no borrowings under the $150.0 million revolving credit facility. The company expects existing cash, investments and borrowing capacity to fund operations for at least 12 months.

Strategically, Vericel continued ramping MACI manufacturing at its Burlington facility and advanced MACI Arthro and the MASCOT ankle study. It entered a BARDA agreement valued at up to $196.9 million for NexoBrid procurement and development, and in July 2026 authorized a $200.0 million open-ended share repurchase program.

Vericel Corporation reported strong second-quarter 2026 results, with total net revenue up 22% to $77.5 million. MACI revenue grew 23% to $65.5 million, and Burn Care revenue rose 22% to $12.0 million. Gross margin was 73%. Net income was $2.2 million, or $0.04 per diluted share, compared with a net loss a year earlier. Non-GAAP adjusted EBITDA was $14.9 million (19% of revenue), and free cash flow was $14.3 million. The company ended the period with approximately $227 million in cash and investments and no debt.

For the first half of 2026, revenue grew 26% to $145.9 million, with MACI at $121.9 million and Burn Care at $24.0 million, and adjusted EBITDA up 47% to $24.4 million. Vericel raised its 2026 guidance to $330–$340 million in total revenue and modestly increased both MACI and Burn Care outlooks, while reaffirming full-year gross margin of about 75% and adjusted EBITDA margin of about 27%. The board also authorized a $200 million share repurchase program, reflecting confidence in the company’s growth and cash generation.

Vericel Corp’s Principal Accounting Officer Jonathan Siegal reported a same-day option exercise and share sale. On June 26, 2026, he exercised 2,500 stock options at $29.82 per share and sold a total of 2,732 common shares at $44.90 per share in open-market transactions.

Following these trades, he holds 886 common shares directly and 6,500 stock options that remain outstanding and exercisable through February 17, 2033. The filing notes the sales were made under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance.